TRA-1-85 (CD147) Antibody, anti-human, REAfinity™
Synonyms: EMMPRIN, Basigin (BSG), Neurothelin, 5F7, BSG, TCSF, OKa, CD147
RECOMBINANT EXTENDED VALIDATION
Bioz Star93/100 Bioz rating
10 Citations1 Image
Clone:
REA476 | TRA-1-85
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, 3D-IF, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:

Related products for TRA-1-85 (CD147) Antibody, anti-human, REAfinity™

Flow cytometry applications
APC
APC-Vio 770
Biotin
PE
PE-Vio 770
Vio Bright FITC
Vio Bright V423
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-128-833, 130-128-900
Description:
Human peripheral blood mononuclear cells (PBMCs) were stained with Anti-TRA-1-85 (CD147) antibodies or with the corresponding REA Control (S) antibodies (left peak). Flow cytometry was performed with the MACSQuant® Analyzer. CD14+ cells were pregated for the analysis. The Tandem Signal Enhancer has been used to increase binding specificity of tandem-dye–conjugated antibodies. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
MICS (MACSima Imaging Cyclic Staining) applications
APC
PE
Fixation:
frozen – Acetone
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-128-833, 130-128-900
Testing grade:
Fixation:
FFPE
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-128-833, 130-128-900
Testing grade:
Fixation:
frozen – PFA
Species tested:
human
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-128-833, 130-128-900
Testing grade:
3D-Immunofluorescence applications
Vio R667
Tissue clearing:
MACS® Clearing Kit
Fixation:
PFA
Species tested:
human
Tissue used:
colorectal cancer
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Conjugate:
Vio R667
Used products:
130-131-642
Description:
3D-immunofluorescence analysis of human colorectal cancer fixed with 4% PFA and subjected to whole-mount immunostaining with CD147 Antibody, anti-human, Vio R667 (red). The sample was processed and optically cleared using the MACS® Clearing Kit and imaged with an UltraMicroscope Blaze light sheet instrument. Sample detail image (A), overview image (B), 3D- rendered maximum intensity projection (C) and 3D-rendered video (D). Scale bars: 200 µm (A), 500 µm (B, C).

Application imageView details view details

Application imageView details view details

Application imageView details view details
Extended validation for TRA-1-85 (CD147) Antibody, anti-human, REAfinity™
Specificity
Epitope competition assay

In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.

Other clones
Overlap in epitope recognition with REA476
TRA-1-85
high
HIM6
low
MEM-M6/1
low
REAL1391
high

Cells were incubated with an excess of purified unconjugated TRA-1-85 (CD147) (REA476) antibody followed by staining with fluorochrome-conjugated antibodies from other known clones targeting the same antigen. Fluorescence intensity was then used to assess epitope overlap: a minimal or absent signal indicated high epitope overlap, an intermediate signal suggested partial overlap, and a strong signal reflected low overlap.

Knockout validation

To ensure antibody specificity, the target gene is knocked out in a suitable cell line using the CRISPR/Cas9 system and the knockout is confirmed by sequencing of the target locus. The antibody is considered to bind specifically to the intended epitope if no antibody binding to the knockout cells can be detected. The antibody staining is controlled by fluorescence microscopy and/or flow cytometry.

WT
Extended-Validation detailed information image
KO
Extended-Validation detailed information image

Fluorescence microscopy image of TRA-1-85 (CD147) knockout cells. Wild type (WT, left) and knockout cells (KO, right) were stained with TRA-1-85 (CD147)-PE (REA476, red) and counterstained with DRAQ5 (blue) as DNA stain.

Extended-Validation detailed information image

Overlay histogram showing flow cytometric analysis of CD147 knockout cells. Wild type (red) and knockout cells (blue) were stained with CD147-PE, clone (REA476). Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells and cell doublets were excluded from the analysis based on scatter signals and propidium iodide fluorescence.

Specifications for TRA-1-85 (CD147) Antibody, anti-human, REAfinity™
Overview

Clone REA476 recognizes the human TRA-1-85 antigen, a single-pass type I membrane protein, which is also known as CD147, basigin, or extracellular matrix metalloproteinase inducer (EMMPRIN). TRA-1-85 is expressed by many cell types, including epithelial cells, endothelial cells, leukocytes, and tumor cells. It is present in vascular endothelium in non-neoplastic regions of the brain, and in tumor cells but not in proliferating blood vessels in malignant gliomas. TRA-1-85 has been implicated in a variety of physiological and pathological activities. It is best known for its ability to function as extracellular matrix metalloproteinase inducer, but has also been shown to regulate lymphocyte responsiveness, monocarboxylate transporter expression, and spermatogenesis. TRA-1-85 is often used to discern human cells from non-human cells in multiple applications including animal transplantation studies.

Additional information: Clone REA476 displays negligible binding to Fc receptors.

Alternative names

EMMPRIN, Basigin (BSG), Neurothelin, 5F7, BSG, TCSF, OKa, CD147

Detailed product information

Technical specifications

Clone
REA476
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
TRA-1-85 (CD147)
Molecular mass of antigen [kDa]
40
Distribution of antigen
leukocytes, endothelial cells, epithelial cells, tumor cells
Entrez Gene ID
RRID
AB_2928935, AB_2921951, AB_2928936, AB_2921968, AB_2905448, AB_2905449, AB_2654243, AB_2654242, AB_2654233, AB_2654232, AB_2654240, AB_2654239, AB_2654241, AB_2654238

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for TRA-1-85 (CD147) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support